Eric K. Singhi, Assistant Professor at MD Anderson Cancer Center, shared a post on X:
“Ladies and gentlemen, we officially have a NEW standard of care in resectable RET fusion+ NSCLC.
LIBRETTO-432: Adjuvant selpercatinib x 3 yrs vs placebo:
- Stage II–IIIA 2-yr EFS: 92% vs 61%
- HR 0.17, P<0.001
Overall stage IB–IIIA:
- 2-yr EFS: 94% vs 70%
- HR 0.16.”
Gavitt Woodard, Thoracic Surgeon at Yale, shared this post, adding:
“Attention thoracic surgeons.
The landscape of NSCLC mutations that need to be tested in your surgical patients is expanding quickly. RET fusion+ NSCLC now has a promising adjuvant treatment option with selpercatinib x3 years.
Great LIBRETTO-432 trial result! ”
LIBRETTO-432 Trial at ASCO 2026 Plenary Session: Adjuvant Selpercatinib in RET Fusion-Positive NSCLC
